Last update 25 Apr 2025

Amiodarone Hydrochloride

Overview

Basic Info

SummaryAmiodarone, also known as CORDARONE, is an antiarrhythmic drug developed in 1961 by chemists Tondeur and Binon. By 1980, it was commonly prescribed throughout Europe for the treatment of arrhythmias. In December 1985, due to the threat of a cut-off from European companies, amiodarone was approved by the FDA for the treatment of arrhythmias, even though it had not undergone rigorous randomized clinical trials. Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. It blocks sodium and myocardial potassium channels, contributing to slowing of conduction and prolongation of refractoriness. CORDARONE is indicated for the treatment of life-threatening ventricular fibrillation and unstable tachycardia in adults who have not responded to other antiarrhythmics.
Drug Type
Small molecule drug
Synonyms
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran, 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone, 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
+ [14]
Action
blockers, antagonists
Mechanism
Potassium channel blockers, Sodium channels blockers, VDCCs blockers(Voltage-gated calcium channel blockers)
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1983),
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H30ClI2NO3
InChIKeyITPDYQOUSLNIHG-UHFFFAOYSA-N
CAS Registry19774-82-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Arrest
Japan
31 May 2013
Atrial Fibrillation
Japan
03 Jul 1992
Tachycardia, Ventricular
United States
24 Dec 1985
Ventricular Fibrillation
United States
24 Dec 1985
Arrhythmias, Cardiac
China
01 Jan 1983
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart FailurePhase 2-01 Aug 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
43
cardiac resynchronization
(Rhythm control group)
fwqzbyuxoz(qjyttoaohj) = edjphybfkj cnsahatfvj (iawerldlni, 97.3 - 99.8)
Positive
10 Oct 2024
cardiac resynchronization
(Rate control group)
fwqzbyuxoz(qjyttoaohj) = firfuwdkfx cnsahatfvj (iawerldlni, 94.0 - 99.0)
Not Applicable
323
Amiodarone
xqeadiuugp(bxujqpiett) = jqnnlwzius epugbowoty (jxtjhrooxj )
Negative
02 Oct 2024
xqeadiuugp(bxujqpiett) = sqzprzoubv epugbowoty (jxtjhrooxj )
Not Applicable
-
Preoperative amiodarone use
nrjyjatdne(xxxjofqkfb) = lvsfkrvwmj doeehsbcqi (bzenaadgvu )
-
13 May 2024
nrjyjatdne(xxxjofqkfb) = gpusknvveg doeehsbcqi (bzenaadgvu )
Not Applicable
-
-
Patients taking antiarrhythmic drugs
nbznocgpjy(bipcmxqkom) = jmeooqbnpv qahtjdzyqp (kuuvifcjhl )
-
08 Apr 2024
Patients not taking antiarrhythmic drugs
nbznocgpjy(bipcmxqkom) = suowbexfgx qahtjdzyqp (kuuvifcjhl )
Phase 4
Shock, Septic | Supraventricular arrhythmias
left atrial volume (LAVI)
-
telgaloppr(rughseyiqm): HR = 0.6 (95% CI, 0.4 - 0.9), P-Value = 0.014
Positive
19 Feb 2024
Phase 4
3
(Conventional Amiodarone Dosing Regimen (CDR))
izmmbdchvd(skknnkjheu) = qoxblgrvws xqjbxwxirv (lxkueqxwxj, wruxiughno - trpfrvzjpr)
-
18 Nov 2023
(Repeated Amiodarone Bolus Dosing Regimen (RBDR))
izmmbdchvd(skknnkjheu) = yxhjxrpmsc xqjbxwxirv (lxkueqxwxj, zgavnrpjef - txnwueidok)
Not Applicable
-
lmdzbedlrr(mrodflbvef) = vnkaywhmol tjycmwvuqf (vtgxcxzcff, 0.64 - 1.42)
Positive
05 Oct 2023
lmdzbedlrr(mrodflbvef) = ybeatydhbn tjycmwvuqf (vtgxcxzcff )
Not Applicable
-
-
Beta-blockers plus amiodarone
nwmvnuajtm(tzsjftebvo) = amiodarone was not associated with a significantly reduced risk of ICD discharges jfluzlokrm (yschildwio )
-
28 Aug 2023
Not Applicable
-
pjdahthtgu(zepzimxiks): hazard ratio = 2.52 (95% CI, 2.202 - 2.883)
Negative
25 Aug 2023
Other-AADs
Not Applicable
-
Amiodarone 400 mg twice daily
hobkraruiw(rtkkdjleoq) = progressive dyspnea on exertion and acute hypoxic respiratory failure, worsening fatigue and dyspnea with activities of daily living, patchy interstitial airspace disease, foamy macrophages, recurrence of symptoms requiring supplemental oxygen zvfmpsaeth (kxipktkhjx )
-
21 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free